ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) [Trend Analysis] retains strong position in active trade, as shares scoring 0.13% to $23.74 in a active trade session, while looking at the shares volume, around 11.68 Million shares have changed hands in this session. . The firm has institutional ownership of 88.00%, while insider ownership included 0.30%. ARIA attains analyst recommendation of 2.70 with week’s performance of 0.42%. Investors looking further ahead will note that the Price to next year’s EPS is -875.00%.
Takeda’s $5.2 billion acquisition of Ariad Pharmaceuticals on Jan. 9 valued the Cambridge cancer drug firm at $24 per share, a 75 percent premium over its previous closing stock price. But it wasn’t until recently that we got some insight into how the companies arrived at that eye-popping figure despite a lack of other bidders. At the time, the companies had been discussing a possible partnership on Ariad’s cancer drug brigatinib, which could win FDA approval in the first half of 2017.
The co is presenting price to cash flow as 14.62. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower. The firm has price volatility of 0.27% for a week and 2.03% for a month. Its beta stands at 2.01 times. Narrow down four to firm performance, its weekly performance was 0.42% and monthly performance was 99.66%.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) runs in leading trade, it jumping up 4.03% to traded at $3.10. MACK attains analyst recommendation of 2.50 on scale of 1-5 with week’s performance of 1.64%. MACK is presenting price to cash flow of 8.42.
Merrimack Pharmaceuticals, Inc. (MACK) announced that Richard Peters, M.D., Ph.D., has been appointed as the Company’s President and Chief Executive Officer, effective February 6, 2017, at which time he will also be appointed to the Merrimack Board of Directors. Dr. Peters will join Merrimack from his current role at Sanofi Genzyme, where he serves as Senior Vice President and Head of Global Rare Diseases. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -66.60%, and looking further price to next year’s EPS is 82.80%. While take a short look on price to sales ratio, that was 3.91.